SpecificationsOrganism/cell line/tissue*Homo sapiens*Strain(s)Primary human ALL specimensSequencer or array typehuman GeneChip U133A Affymetrix, human Genome-Wide SNP 6.0 Array AffymetrixData formatRaw data: TAR, normalized data: SOFT, MINiML, TXTExperimental factorsExpression profiling and genome-wide copy number variation profiling in B-precursor ALL of childhoodConsentAll primary ALL samples were obtained with written informed consent of patients\' parents or their legal guardians

Direct link to deposited data {#s0010}
=============================

Deposited data can be found here: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42221> and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42056>.

Experimental design, materials and methods {#s0015}
==========================================

Patient samples {#s0020}
---------------

All primary human samples were obtained upon approval by Institutional Ethics Boards. Patients were recruited by the COALL multicenter clinical trial group (Germany) and enrolled in trials COALL 97 and 03. For patient characteristics and clinical data refer to [Table 1](#t0005){ref-type="table"}. Mononucleated cells (MNC) from bone marrow or peripheral blood were processed by gradient centrifugation (Biocoll separation solution, Biochrom) and cryopreserved.

Gene expression array {#s0025}
---------------------

For a comparative matched pair expression analysis, single primary leukemic cells and normal lymphoblasts were isolated from the same individual, using a MoFlow Cytomation instrument by CD34, CD10 and CD19 staining. Please note that primary ALL I4 had a blast fraction of greater than 95% and was included without single cell sort due to experimental circumstances. Total RNA was isolated from a minimum of 4 × 10^3^ mononucleated cells. Quality and concentration of isolated RNA were determined using an Agilent RNA 6000 Nano kit on an Agilent Bioanalyzer. Total RNA underwent linear amplification in a two-step procedure and was labeled and hybridized to each array according to the manufacturer\'s instructions using the small sample protocol. Human GeneChip U133A arrays (Affymetrix) were then washed using the Affymetrix Fluidics Station 400 and scanned using a HP GeneArray scanner. The array image was acquired using the Affymetrix GeneChip Microarray Suite 5.0. Software. The samples were normalized using the MAS5 method and scaled to a target value of 100.

Quality control {#s0030}
---------------

We used Bioconductor packages (simpleaffy [@bb0010] and arrayQualityMetrics [@bb0015]) to assess the quality of the array experiment. As shown in [Fig. 1](#f0005){ref-type="fig"}, samples are affected by slight degradation likely due to the elaborate cell selection and material isolation procedures followed by two amplification steps. In addition, a slight batch effect can be observed. Nevertheless, good sample comparability is given, because the degree of degradation is almost identical across all samples and the batch effect, which manifests as an overall higher signal intensity in one group, is readily eliminated during the normalization process.

Basic microarray analysis {#s0035}
-------------------------

The expression data of primary ALL at diagnosis (I1s, I2s, I3s, and I4; s, sorted cellular material) were independently filtered based on defined cutoff criteria such as present call, signal intensity (SI) ≥ 20, increase (I) or decrease call (D), change P value ≤ 0.003 for I/≥ 0.997 for D and signal log ratio (SLR) ≥ 0.5849 for I/≤− 0.415 for D (equivalent to 1.5 × up- or down-regulation), which arose from the comparison with the corresponding remission material (E1s, E2s, E3s, and E4s) as control. In all comparisons initial scaling was set to a target signal of 100. All genes meeting these cutoff criteria were considered to be differentially expressed, as depicted in the heatmap.

Quantitative real-time PCR {#s0040}
--------------------------

Ahead of high-resolution genomic profiling ZNF423 expression was evaluated by quantitative real time PCR (qPCR) in 200 primary B-precursor ALL samples. For this purpose RNA isolation was performed after TRIZOL lysis (Invitrogen) according to manufacturer\'s instructions. TRIZOL-isolated RNA was reverse transcribed to cDNA by M-MLV reverse transcriptase for 1 h at 37 °C using random primers (Promega). qPCR was carried out with SYBR Green I (Roche) according to manufacturer\'s instructions using following primers: *ZNF423* ([NM_015069.2](ncbi-n:NM_015069.2){#ir0445}) fw: 5′-gca gac ctg acg gac cac-3′ and rev-5′-agg cca ccc agg aga gtt-3′; and *beta-2-microglobulin* (*B2M*, [NM_004048](ncbi-n:NM_004048){#ir0450}) fw: 5′-ttc tgg cct gga ggc tatc-3′ and rev: 5′-tca gga aat ttg act ttc cat tc-3′. Relative mRNA levels were depicted after normalization to *B2M* (2^− ΔCt^\*1000) as a reference gene. For genomic profiling ALL samples from 20 patients that showed a significantly higher ZNF423 expression than hematopoietic/lymphopoietic progenitors at various stages of development, were selected.

High resolution genomic profiling {#s0045}
---------------------------------

Genomic DNA was isolated from 20 initial ALL samples and intraindividually matched mononuclear cells (MNC) from remission bone marrow using the QIAGEN DNA Blood Mini Kit following the manufacturer\'s instructions. Sample preparation, hybridization and staining were performed according to the manufacturer\'s standard protocol for Affymetrix Genome-Wide Human SNP 6.0 microarrays. Arrays were scanned on an Affymetrix 3000 7G GeneChip scanner using the Affymetrix Command Console Software. Processing of the raw signals and raw copy-number calculation were performed using the CRMA (version 2) procedure (Aroma, Affymetrix Package Version 2.0.0) for R statistical platform (version 2.12.1) according to the Aroma Affymetrix vignette for paired total copy-number analysis. CBS algorithm (DNA copy package version 1.24.0) was then applied to perform segmentation. Quality was accessed using the Contrast QC metric recommended by Affymetrix and displayed in [Table 2](#t0010){ref-type="table"}.

Discussion {#s0005}
==========

In this report we provide an extended description of materials and methods for two datasets deposited in the GEO database containing gene expression and high-resolution genomic profiling data. The corresponding biologic material was isolated from fluorescence activated sorted primary leukemic cells (except one case) and normal lymphoblasts (gene expression data) as well as from 20 initial ALL and intraindividually matched MNC from remission bone marrow (genomic data). Based on these data we identified a potentially causative role for ZNF423 in ALL by its interference with B-cell differentiation and modulation of Smad1--Smad4 dependent transcription [@bb0005]. We encourage the use of our deposited datasets for further investigation into mechanistic underpinnings of ALL. We will provide further information if needed.

![Quality metrics for gene expression dataset [GSE42221](ncbi-geo:GSE42221){#ir0230}. (A) The rate of present calls (%), scaling factors (blue bars) as well as 3′ to 5′ ratios for ß-*ACTIN* and *GAPDH* were calculated by the simpleaffy package. (B) The dissimilarity matrix of the arrays ahead of normalization shows a batch effect that is linked to hybridization date. (C) This effect is eliminated by the background and normalization procedure. The scores displayed in the dissimilarity matrices (blue: high similarity, yellow: low similarity) reflect the distance between each pair of arrays. They are computed as the mean absolute difference between the array data.](gr1){#f0005}

###### 

Patient characteristics. M, male; F, female; C-ALL, common ALL; NA, not available.

  ID     Sex   Immuno-phenotype   BCR--ABL   MLL--AF4   ETV6--RUNX1   Hyper-diploidy   *ZNF423* mRNA expression
  ------ ----- ------------------ ---------- ---------- ------------- ---------------- --------------------------
  6646   M     C-ALL              0          NA         0             1                36.23
  6787   M     preB-ALL           NA         NA         NA            0                17.00
  6822   M     C-ALL              0          0          1             0                24.97
  6845   M     C-ALL              0          NA         0             NA               51.38
  6869   M     C-ALL              0          0          0             1                7.91
  6923   M     preB-ALL           NA         NA         NA            0                22.20
  6924   M     C-ALL              0          0          0             0                9.79
  6965   F     C-ALL              0          0          1             0                19.08
  6992   F     preB-ALL           0          0          1             NA               18.81
  7021   M     C-ALL              0          0          1             0                39.56
  7065   M     C-ALL              0          0          0             0                8.71
  7077   M     C-ALL              0          0          1             NA               27.48
  7115   M     C-ALL              0          0          1             0                47.38
  7118   M     C-ALL              0          0          0             0                20.88
  7137   F     proB-ALL           0          0          0             0                13.54
  7191   F     C-ALL              0          0          1             0                69.07
  7293   F     C-ALL              0          0          1             0                6.52
  7360   M     C-ALL              0          0          1             0                17.42
  7503   M     C-ALL              0          0          1             0                27.27
  7523   F     C-ALL              0          0          1             0                26.80

###### 

Affymetrix SNP array quality metrics.

  GEO accession                                Sample name          Contrast QC   QC call rate
  -------------------------------------------- -------------------- ------------- --------------
  [GSM1031509](ncbi-geo:GSM1031509){#ir0235}   ALL 6869 initial     1.00          94.04
  [GSM1031510](ncbi-geo:GSM1031510){#ir0240}   ALL 6845 initial     1.43          94.01
  [GSM1031511](ncbi-geo:GSM1031511){#ir0245}   ALL 6646 initial     1.77          95.33
  [GSM1031512](ncbi-geo:GSM1031512){#ir0250}   ALL 7021 initial     1.24          91.99
  [GSM1031513](ncbi-geo:GSM1031513){#ir0255}   ALL 6923 initial     2.14          95.43
  [GSM1031514](ncbi-geo:GSM1031514){#ir0260}   ALL 7077 initial     2.29          95.2
  [GSM1031515](ncbi-geo:GSM1031515){#ir0265}   ALL 7191 initial     2.04          96.13
  [GSM1031516](ncbi-geo:GSM1031516){#ir0270}   ALL 7115 initial     1.21          91.53
  [GSM1031517](ncbi-geo:GSM1031517){#ir0275}   ALL 7360 initial     2.02          97.15
  [GSM1031518](ncbi-geo:GSM1031518){#ir0280}   ALL 7065 initial     1.93          94.97
  [GSM1031519](ncbi-geo:GSM1031519){#ir0285}   ALL 6965 initial     1.67          95.96
  [GSM1031520](ncbi-geo:GSM1031520){#ir0290}   ALL 7503 initial     2.14          95.47
  [GSM1031521](ncbi-geo:GSM1031521){#ir0295}   ALL 7523 initial     2.18          96.03
  [GSM1031522](ncbi-geo:GSM1031522){#ir0300}   ALL 6992 initial     2.02          96.03
  [GSM1031523](ncbi-geo:GSM1031523){#ir0305}   ALL 6787 initial     2.32          97.25
  [GSM1031524](ncbi-geo:GSM1031524){#ir0310}   ALL 6924 initial     1.68          93.28
  [GSM1031525](ncbi-geo:GSM1031525){#ir0315}   ALL 7137 initial     2.49          97.88
  [GSM1031526](ncbi-geo:GSM1031526){#ir0320}   ALL 6822 initial     2.79          95.57
  [GSM1031527](ncbi-geo:GSM1031527){#ir0325}   ALL 7118 initial     4.26          95.6
  [GSM1031528](ncbi-geo:GSM1031528){#ir0330}   ALL 7293 initial     2.07          97.29
  [GSM1031529](ncbi-geo:GSM1031529){#ir0335}   ALL 6869 remission   1.75          93.81
  [GSM1031530](ncbi-geo:GSM1031530){#ir0340}   ALL 6845 remission   1.21          94.57
  [GSM1031531](ncbi-geo:GSM1031531){#ir0345}   ALL 6646 remission   1.66          94.71
  [GSM1031532](ncbi-geo:GSM1031532){#ir0350}   ALL 7021 remission   1.87          94.11
  [GSM1031533](ncbi-geo:GSM1031533){#ir0355}   ALL 6923 remission   1.95          96.23
  [GSM1031534](ncbi-geo:GSM1031534){#ir0360}   ALL 7077 remission   2.29          95.43
  [GSM1031535](ncbi-geo:GSM1031535){#ir0365}   ALL 7191 remission   1.72          94.08
  [GSM1031536](ncbi-geo:GSM1031536){#ir0370}   ALL 7115 remission   1.98          94.34
  [GSM1031537](ncbi-geo:GSM1031537){#ir0375}   ALL 7360 remission   0             93.58
  [GSM1031538](ncbi-geo:GSM1031538){#ir0380}   ALL 7065 remission   2.62          97.58
  [GSM1031539](ncbi-geo:GSM1031539){#ir0385}   ALL 6965 remission   1.57          94.57
  [GSM1031540](ncbi-geo:GSM1031540){#ir0390}   ALL 7503 remission   1.7           94.61
  [GSM1031541](ncbi-geo:GSM1031541){#ir0395}   ALL 7523 remission   1.97          95.6
  [GSM1031542](ncbi-geo:GSM1031542){#ir0400}   ALL 6992 remission   1.99          95.93
  [GSM1031543](ncbi-geo:GSM1031543){#ir0405}   ALL 6787 remission   2.12          97.32
  [GSM1031544](ncbi-geo:GSM1031544){#ir0410}   ALL 6924 remission   2.17          96.29
  [GSM1031545](ncbi-geo:GSM1031545){#ir0415}   ALL 7137 remission   2.18          96.62
  [GSM1031546](ncbi-geo:GSM1031546){#ir0420}   ALL 6822 remission   2.41          95.9
  [GSM1031547](ncbi-geo:GSM1031547){#ir0425}   ALL 7118 remission   1.91          92.55
  [GSM1031548](ncbi-geo:GSM1031548){#ir0430}   ALL 7293 remission   1.42          94.28

[^1]: These authors contributed equally to this work.
